State Street
FHTX icon

State Street’s Foghorn Therapeutics FHTX Stock Holding History

State Street’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
679,787
+61,121
+10% +$336K ﹤0.01% 3130
2025
Q4 		$3.34M Sell
618,666
-18,482
-3% -$83.8K ﹤0.01% 3155
2025
Q3 		$3.12M Buy
637,148
+93,501
+17% +$496K ﹤0.01% 3185
2025
Q2 		$2.56M Sell
543,647
-42,570
-7% -$178K ﹤0.01% 3223
2025
Q1 		$2.14M Buy
586,217
+18,850
+3% +$85.9K ﹤0.01% 3220
2024
Q4 		$2.68M Buy
567,367
+61,422
+12% +$447K ﹤0.01% 3221
2024
Q3 		$4.71M Buy
505,945
+23,630
+5% +$171K ﹤0.01% 2999
2024
Q2 		$2.77M Buy
482,315
+44,651
+10% +$266K ﹤0.01% 3187
2024
Q1 		$2.94M Buy
437,664
+15,034
+4% +$83.5K ﹤0.01% 3143
2023
Q4 		$2.73M Sell
422,630
-11,240
-3% -$48.5K ﹤0.01% 3209
2023
Q3 		$2.17M Sell
433,870
-5,397
-1% -$41.6K ﹤0.01% 3293
2023
Q2 		$3.09M Buy
439,267
+29,754
+7% +$208K ﹤0.01% 3218
2023
Q1 		$2.54M Buy
409,513
+5,375
+1% +$35.2K ﹤0.01% 3259
2022
Q4 		$2.58M Buy
404,138
+32,520
+9% +$245K ﹤0.01% 3297
2022
Q3 		$3.19M Buy
371,618
+1,586
+0.4% +$20.4K ﹤0.01% 3270
2022
Q2 		$5.03M Buy
370,032
+51,807
+16% +$669K ﹤0.01% 3101
2022
Q1 		$4.85M Buy
318,225
+15,651
+5% +$215K ﹤0.01% 3195
2021
Q4 		$6.92M Buy
302,574
+77,554
+34% +$1.11M ﹤0.01% 3094
2021
Q3 		$3.13M Buy
225,020
+35,621
+19% +$394K ﹤0.01% 3480
2021
Q2 		$2.02M Buy
189,399
+80,300
+74% +$875K ﹤0.01% 3546
2021
Q1 		$1.44M Buy
109,099
+7,303
+7% +$120K ﹤0.01% 3545
2020
Q4 		$2.06M Buy
+101,796
New +$1.95M ﹤0.01% 3367

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street's FHTX Position: Q1 2026 in Review

State Street increased its Foghorn Therapeutics (FHTX) stake by 9.9% in Q1 2026, buying an estimated $336K and bringing the position to 679,787 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

State Street first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $6.92M in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • State Street held 679,787 shares of Foghorn Therapeutics worth $3.25M as of Q1 2026.
  • State Street bought 61,121 Foghorn Therapeutics shares in Q1 2026, an estimated $336K.
  • Foghorn Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3130 holding.
  • State Street first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • State Street's Foghorn Therapeutics position peaked at $6.92M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.